Nurse’s guide to IXEMPRA therapy
This practical guide includes dosing calculations for preparing IXEMPRA® (ixabepilone) for infusion, a review of indications/contraindications, and tables that summarize dose modifications for toxicities and special populations.
Dosing and administration guide
Use this brochure as a quick guide for dosing and administration of IXEMPRA monotherapy and combination therapy with capecitabine.
Pharmacy fact sheet
For a reference for how IXEMPRA is supplied (the 15-mg and 45-mg IXEMPRA Kits), use this pharmacy fact sheet, which includes recommended dosing, premedication, and dose modifications for toxicities and special populations.
Patient brochure
This brochure explains to patients what to expect while being treated with IXEMPRA. This resource lists the indications for IXEMPRA and describes the signs and symptoms of common side effects and the more serious adverse reactions, including peripheral neuropathy, neutropenia, and hypersensitivity.
Ixabepilone Review Article: July 2021
Review of effectiveness, safety, and tolerability. Ixabepilone is approved as monotherapy and in combination with capecitabine for the treatment of metastatic breast cancer in patients with demonstrated resistance to anthracyclines and taxanes. Portions of this article may contain information not included in the approved IXEMPRA labeling.
Study 046: Combination therapy
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment. Portions of this journal article may contain information not included in the approved IXEMPRA labeling.
Study 081: Monotherapy
Efficacy and Safety of Ixabepilone (BMS-247550) in a Phase II Study of Patients With Advanced Breast Cancer Resistant to an Anthracycline, a Taxane, and Capecitabine. Portions of this journal article may contain information not included in the approved IXEMPRA labeling.
IXEMPRA combination speaker program deck
View this educational slide deck, which includes an overview of breast cancer and factors associated with poor prognosis, as well as the clinical data for IXEMPRA combination therapy.
IXEMPRA monotherapy speaker program deck
View this educational slide deck, which includes IXEMPRA indications and usage and the clinical data for its use as monotherapy.
Prescriber perspectives
Solving for Treatment Resistance in Metastatic or Locally Advanced Breast Cancer
IXEMPRA (Ixabepilone) for advanced triple-negative breast cancer
Clinical activity with evolved disease
Managing toxicities associated with IXEMPRA
Ideal patients for IXEMPRA
